Investor Presentaiton slide image

Investor Presentaiton

Innovation: gepotidacin - a potential novel antibiotic to treat uUTI¹ Outpatient antibiotic resistance rates highlight need for new antibiotics Annual incidence in women c.12% 15m episodes annually in US c.30% of UUTI patients experience 1 or more failures 40% of women feel symptoms restrict daily activities Large addressable patient Burden of disease population C High Treatment antibiotic failure resistance rates >20% resistance to FQ2 and SXT3 agents Diminishing utility of existing antibiotic classes for uUTI6 30% 25% 25% 20% 20% 15% 10% 5% 0% 7% 3% Proportion of E. coli Isolates (%) | SXT NS (n=67,189) ESBL+ (n=19,576) FQ NS (n=54,359) NFTONS (N=9,453) 1. Uncomplicated urinary tract infection 2. Fluoroquinolone 3. Trimethoprim sulfamethoxazole 4. Extended spectrum beta lactamases 5. Nitrofurantoin 6. Kaye KS, Gupta V, Mulgirigama A, Joshi A, Scangarella-Oman N, Yu K, Ye G, and Mitrani-Gold FS. Trends in Antimicrobial Resistance Among Outpatient Urine E. coli Isolates in US Females ≥12 Years of Age: A Multicenter Evaluation From 2011 to 2019. Oral and Abstract/Poster presentation 1698, ID week, Oct. 21-25 2020. GSK 13
View entire presentation